Design for Transition: Nachhaltige Transformation gestalten

Design for Transition: Nachhaltige Transformation gestalten
Go back

Zukunftsfähigkeit gestalten: Konkrete Ansätze für Ihr Unternehmen

Hohe Energiepreise, Ressourcenknappheit, Lieferkettenprobleme, sowie steigender Regulierungs- und Transformationsdruck.

Wie können Unternehmen in diesem Umfeld fundierte Entscheidungen treffen und langfristig wettbewerbsfähig bleiben?

Das Fraunhofer HNFIZ Transformation & Governance entwickelt praxisnahe Angebote für genau diese Herausforderungen.

  1. Intensivtraining „Design for Transition“

Im Training lernen Teilnehmende:

  • Komplexe Situationen strukturieren und Risiken sichtbar machen – auf Basis des Transition-Design-Ansatzes (Carnegie Mellon University, USA)
  • Wechselwirkungen verstehen und fundierte Entscheidungen auch unter Unsicherheit treffen
  • Zielkonflikte in Transformationsprozessen bewusst steuern
  • Tragfähige Strategien für dynamische Unternehmenskontexte entwickeln
  • KI-gestützte Methoden (Prompting) gezielt einsetzen

Termine (aufeinander aufbauend):

  1. Juni 2026 (Präsenz, Heilbronn)
  2. Juli 2026 (online)

Teilnahmegebühr: 89 €

Details zur Veranstaltung

Datum

Tag 1: 30.06.2026 (10 – 17 Uhr (präsenz))

Tag 2: 28.07.2026 (10 – 17 Uhr (online))

Ort
Urban Innovation Hub
Sülmerstraße 21
74072 Heilbronn
Referent
Dr. Anh Mattick,
Barbara Klobucaric,
Fabian Brodbeck
register now

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp